The therapeutic effects of cinnarizine in patients with circulatory disorders have been repeatedly described. Many controlled clinical trials have confirmed the usefulness of the drug both in cerebrovascular (Rebello de Mattos 1971 , Amery & Oosterveld 1975 , Staessen 1977 and in peripheral obliterative arterial diseases (Alexander 1970 , Caesar 1971 , Joos 1968 ). In a previous paper we demonstrated that both short and long term cinnarizine therapy increased blood flow in the lower limbs, both in subjects affected by obliterative arterial diseases and in normal subjects (Forconi et al. 1976 ). This property of the drug was also noted by Verhaegen et al. (1974) , Ellis et al. (1975) and Schuermans et al. (1971) and it was attributed to the inhibition of the calcium-induced contraction of the vascular smooth muscle (Godfraind & Sturbois 1975 , Van Nueten & Janssen 1973 , probably because it reduced calcium transfer to the muscular fibrocell (Godfraind et al. 1973) .
More recently, further study of the relationship between blood flow and blood viscosity has led to the hypothesis of the existence of a reciprocal control at the microcirculatory level. Such aspects as the viscosity of blood and the factors influencing it (plasma and serum viscosity, fibrinogen concentration, hematocrit and possibly red cell aggregation or deformability) have been seriously reconsidered (Dintenfass 1971 , Dormandy 1970 , Ehrly 1976a , Schmid-Schombein 1976 , Phillips & Harkness 1976 .
The effect of blood flow in increasing activity of pharmacological agents could be due either to a direct action on the vessel wall followed by a reduction of circulatory resistance, or to an effect on blood viscosity. Since cinnarizine undoubtedly influences the peripheral circulation, thus increasing the muscular blood flow, the possibility of a specific effect on blood viscosity may be postulated. The aim of the present investigation was to examine this hypothesis in man.
Patients and Methods
The investigation was designed to study the action of cinnarizine on blood viscosity both after a single dose and after 1 week of treatment.
Twenty-five subjects affected with peripheral obliterative arterial disease of the lower legs and suffering from intermittent claudication were included in the study. They were divided into two groups. Fourteen patients (10 males and 4 females, mean age ±s.e.=59±3 years; mean weight±s.e. =68±4 kg) took part in the single dose study. Eleven patients (9 males and 2 females, mean age ±s.e.=65±2 years; mean weight±s.e.=67±3 kg) were included in the one-week study.
The diagnosis of peripheral obliterative arterial disease was confirmed in all patients by the significant reduction of post-ischemic flow measured by venous occlusion strain gauge plethysmography (Forconi et al. 1974 (Forconi et al. , 1977 . In the first group of patients arterial disease was associated with diabetes in 2 cases, with hypothyroidism in 1 case, with angina pectoris in 1 case, with essential hypertension in 1 case and with essential hypertension, angina pectoris and cerebral stroke in 1 case. In the second group there were 2 diabetics and 1 hypertensive patient. One of the diabetic patients had had a stroke.
Cinnarizine was supplied in an alcoholic solution of 75 mg/ml. In the single dose study, each subject received 300 mg of cinnarizine orally in the early morning. Blood samples were taken from an antecubital vein before the administration of the drug, and after 90 and 180 min. In the oneweek study each subject received 75 mg of cinnarizine 3 times daily for 7 days. Blood samples were taken before the first administration and on the morning of the eighth day, 8 h after the last administration of the drug.
Blood samples were treated with the following anticoagulants: EDTA 10% (0.1 ml in 8 ml of blood) for whole blood and plasma viscosity measurements; sodium citrate 3.8% (0.5 ml in 4.5 ml of blood) for fibrinogen determination and a minimum amount of heparin sodium for osmolality determinations.
Fluid Estimations
The following estimations were performed on each sample:
(1) Blood, plasma and serum viscosity by a Wells-Brookfield cone/plate 1/4 RVT viscometer at 37°C at shear rates of 750, 375, 150, 75, 37.5, 18.75, 7 .50 and 3.75/sec. Plasma and serum determinations were performed at a shear rate of 750/sec since plasma and serum are considered to be newtonian fluids, which do not vary their viscosity with changing shear rates.
(2) Hxematocrit (%).
(3) Plasma fibrinogen concentration by nephelometry using the formation of antigen-antibody complexes measured with the fluornephelometer of an Autoanalyzer Technicon II, continuous viscosity had decreased significantly by 90 min flow AIP system. and even more by 180 min after the administra-(4) Plasma osmolality by a Knauer osmometer.
tion of the drug. At 180 min the percentage decrease was only slightly higher at the lowest Results
(3.5/sec=16%) than at the highest rate (750/sec Table I gives results for the single-dose study and =11.7%, Fig 1) . Table 2 for the one-week study. Statistical A slight decrease was observed in plasma analysis was performed using Student's t test for viscosity and fibrinogen concentration but the paired variables, the mean values after treatment changes were not significant. No variations were being compared with mean pre-treatment values. noted in serum viscosity, hmematocrit or plasma All the subjects affected by obliterative arterial osmolality. disease had higher blood viscosity values before Results were similar in the one-week study. treatment than the group of 45 normal subjects Blood viscosity showed a highly significant previously studied (Di Perri et al. unpublished) , decrease at all shear rates measured. The decrease a finding which agrees with those of other authors was slightly greater at the lowest rates (3.75/sec (Dintenfass et al. 1966 , Bartoli et al. 1969 .3%) than at the highest (750/sec= 11 %) as Bydgemann & Wells 1969, Dormandy, Hoare, noted in the single-dose study (Fig 2) . Similarly, Colley et al. 1973 , Dormandy, Hoare, Khattab the slight decrease in plasma and serum viscosity et al. 1973 , Stormer et al. 1974 , Ehrly 1976b , and in fibrinogen concentration was not signifi -Brunetti etal. 1974) .
cant, and no variations in hematocrit or plasma In the single-dose study of cinnarizine, blood osmolality were observed. These findings clearly demonstrate that acutely as well as chronically administered cinnarizine significantly lowers blood viscosity in subjects with increased viscosity values. After seven days of treatment, normal viscosity levels were reached. The main factors influencing whole blood viscosity are red cells and plasma viscosity. Red cells may influence whole blood viscosity either because of their number (haematocrit) or their physicochemical characteristics, such as aggregation, deformability or internal viscosity. Plasma viscosity, through fibrinogen concentration, may affect whole blood viscosity either directly or by modifying the rate of red cell aggregation (Chien et al. 1971 , Wells et al. 1964 or red cell deformability itself ). Serum viscosity depends on the density, charge, size and shape of the dissolved proteins (Wells 1970 ) but its contribution to whole blood viscosity is not important, except in serum protein disorders (Perry & Clark Hoagland 1976 , Somer 1966 , McGrath & Penny 1976 .
These findings do suggest that cinnarizine decreases whole blood viscosity by any action on serum or on plasma viscosity. The slight decrease in the latter and in plasma fibrinogen concentration was not significant and could not directly influence blood viscosity. Hamatocrit values were also unaffected.
Cinnarizine therefore seems to influence characteristics of the red cell, such as internal viscosity, aggregation or deformability. It seems improbable that cinnarizine changes internal red cell viscosity which depends on the type and content of hemoglobin (Dintenfass 1962) and which increases in hmmatological disorders such as sickle-cell anemia (Klug et al. 1974) . The slight and non-significant decrease in fibrinogen concention also suggests that red cell aggregation is not greatly affected by the drug. However, aside from its relationship with fibrinogen concentration, this mechanism is not to be completely excluded.
Previous reports on cinnarizine have indicated that the activity of the drug on vascular smooth muscle may be due to an inhibition of the calcium channels of the menmbrane of the fibrocell itself (Godfraind & Sturbois 1975 , Van Nueten & Janssen 1973 , Godfraind et al. 1973 . A similar membrane mechanism may be postulated for all human cells including the erythrocyte, and membrane changes have a considerable effect on erythrocyte deformability (Ehrly 1976b , Schmid-Schombein 1976 . Increased deformability of red cells leading to a decrease in blood viscosity cannot therefore be excluded. This hypothesis is now being examined in this laboratory where measurements of red cell filtrability are being performed according to the method suggested by .
Summary
The action of cinnarizine on blood viscosity was studied in patients affected by peripheral obliterative arterial diseases. Both the acute and the chronic administration of the drug diminished the increased whole blood viscosity in patients without affecting plasma and serum viscosity, hxmatocrit, plasma fibrinogen concentration or plasma osmolality. Since cinnarizine also led to a significant increase in peripheral muscular blood flow, it was postulated that this action might be due to an increased deformability of the red cells and may play a considerable role in therapeutic approaches to such arterial diseases.
